Loading
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Previous close
$5.655
−$0.205 · -3.50%
After-hours
$5.655
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $5.655
52-week range
Current $5.655
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
11
Overpriced
Sentiment
73
Bullish
Risk
54
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $5.655
52-week range
Current $5.655
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1M USD | 5.72M USD | 1.66M USD | 652K USD | 30.02M USD |
| Cost of goods sold | 2.95M USD | 4.89M USD | 4.04M USD | 82.2M USD | 1.38M USD |
| Gross profit | −1.95M USD | 827K USD | −2.39M USD | −81.55M USD | 28.64M USD |
| Research and development | 35.27M USD | 67.21M USD | 74.31M USD | 82.9M USD | 56.56M USD |
| Selling, general, and administrative | 17.24M USD | 19.08M USD | 19.3M USD | 19.68M USD | 18.72M USD |
| Operating expenses | 49.56M USD | 81.39M USD | 89.57M USD | 21.78M USD | 73.91M USD |
| Interest income | 2.7M USD | 5.17M USD | 4.67M USD | 1.59M USD | 625K USD |
| Depreciation and amortization | 3.69M USD | 3.83M USD | 4.04M USD | 3.07M USD | 1.38M USD |
| Operating income | −51.51M USD | −80.57M USD | −91.96M USD | −103.33M USD | −45.27M USD |
| Net income | −48.81M USD | −75.41M USD | −87.3M USD | −101.95M USD | −44.97M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.59M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM12.44M0.02%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI11.25M0.11%10.08B USD0.35%$150.23-0.44%
Vanguard Extended Market ETFVXF5.45M0.01%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO3.91M0.03%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO2.47M0.01%18B USD0.06%$112.21-1.26%
Fidelity Enhanced Small Cap ETFFESM2.28M0.03%6.41B USD0.28%$45.22-1.14%
Vanguard Health Care ETFVHT1.53M0.01%22B USD0.09%$315.31+0.78%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
